The short version
7 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Methylergonovine Maleate
Methylergonovine Maleate · METHYLERGONOVINE MALEATE .2 mg/1 · Tablet · Oral · Rising Pharma Holdings, Inc.
NDC 16571-0735-01 · 100 TABLET in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for methylergonovine maleate (oral solid) in the next 90 days
sole-source market · 1 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,790.97 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA211919
- TE code
- AB
- Approval date
- Jan 15, 2021
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Methylergonovine Maleate (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| American Health Packaging | METHYLERGONOVINE MALEATE .2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Granules Pharmaceuticals Inc. | METHYLERGONOVINE MALEATE .2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Lupin Pharmaceuticals,Inc. | METHYLERGONOVINE MALEATE .2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | METHYLERGONOVINE MALEATE .2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rising Pharma Holdings, Inc. | METHYLERGONOVINE MALEATE .2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | METHYLERGONOVINE MALEATE .2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Volley Pharmaceuticals, LLC | METHYLERGONOVINE MALEATE .2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Methylergonovine Maleate — NDC 16571-0735-01," retrieved September 3, 2026, https://drugdashboards.com/drug/16571073501.
Free to cite with attribution — see how the data is put together.